Menu Back toTOPIC-5-SESSION-5-Effectiveness-of-Risk-Minimisation-Measures

Joint MHRA/DIA Excellence in Pharmacovigilance

This course is designed to provide a firm grounding in key aspects of European Clinical Pre- and Post-Marketing Safety regulatory requirements.


TOPIC 5 SESSION 5: Effectiveness of Risk Minimisation Measures

Session Chair(s)

Gaby L. Danan, MD, PhD

Gaby L. Danan, MD, PhD

  • Pharmacovigilance Expert
  • GLD, France
Phil  Tregunno

Phil Tregunno

  • Group Manager, Vigilance, Intelligence and Research Group
  • Medicines and Healthcare Products Regulatory Agency (MHRA), United Kingdom

Speaker(s)

Jan  Petracek

Effectiveness of Risk Minimisation Measures

Jan Petracek

  • Director
  • Institute of Pharmacovigilance, Czech Republic

Contact us


Registration Questions

Send Email
+41 61 225 51 51



Agenda and Logistics

Send Email
+41 61 225 51 55